PF-07820435 + sasanlimab

PF-07820435 + sasanlimab is a combination therapy evaluated for the treatment of advanced or metastatic solid tumors. PF-07820435 is an orally available small molecule agonist targeting the stimulator of interferon genes (STING) pathway, designed to promote anti-cancer immunity by activating type I interferon responses and other inflammatory mediators. Sasanlimab is a subcutaneously administered monoclonal antibody that acts as a programmed death-1 (PD-1) inhibitor, enhancing immune system activity against tumor cells by blocking the PD-1 checkpoint pathway. The combination aimed to synergistically activate innate and adaptive immunity in solid tumors. Both agents were developed by Pfizer. The clinical trial for this combination in solid tumors was terminated for strategic business reasons, not due to safety or efficacy concerns[1][2][6][7].